Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

stated it was seeking "preliminary injunctive relief to enforce a standstill agreement and a trial on a paper record on an expedited basis," according to Endpoints News. Last week, Biogen (NASDAQ ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an ... Sage said it’s “seeking preliminary injunctive relief to enforce a standstill agreement and a trial ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Biogen BIIB and Japan-based partner ... The new option provides relief to AD patients taking Leqembi, as IV administrations are time-consuming — nearly one hour for each infusion.